Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, hav announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies.
“We are thrilled to announce the partnership with Lunaphore and combine Lunaphore’s best-in-class flagship Comet, a hyperplex staining and imaging platform, with Nucleai’s Atom platform that uniquely supports multiplex, IHC, and H&E data,” said Avi Veidman, Chief Executive Officer of Nucleai. “This strategic partnership will allow us to utilise multiplex technology and provide a complete, actionable, and scalable solution to improve drug target discovery and development of our pharma and biotech partners.”
Mapping biological microenvironments with spatial mapping technology is an exciting area of discovery. Lunaphore’s novel Comet technology unlocks the power of immunofluorescence spatial biology with a robust and user-friendly system, permitting the use of any non-conjugated antibodies and enabling the wide adoption of spatial biology in laboratories. Nucleai has built a platform that makes spatial analysis scalable and operational, enabling the next generation of actionable insights from massive pathology data sets that have not been analysed to their fullest potential and could provide significant value to pharmaceutical companies and diagnostic labs.
The partnership will utilise Lunaphore’s innovative Comet platform for hyperplex staining and imaging with Nucleai’s cutting-edge AI spatial models to derive new insights from tissue biopsies, including novel drug targets, mechanisms of action, and biomarkers to advance the field of precision medicine. The combined solutions will provide laboratories with an integrated end-to-end spatial biology workflow from automated, hyperplex sequential immunofluorescence staining and imaging to AI-enabled, state-of-the-art image processing, and data analytics. As part of the partnership, the companies also plan to develop predictive and prognostic spatial biomarker assays.
“Our partnership with Nucleai is based on our shared vision to advance next-generation spatial multiplex immunofluorescence imaging to accelerate drug and biomarker discovery and development,” said Déborah Heintze, Chief Marketing Officer of Lunaphore. “Connecting Nucleai’s solution with Comet, we have the potential to more precisely characterise the immune system and disease microenvironment to provide deeper biological insights to drug developers.”
Comet is a fully automated sequential immunofluorescence (seqIF) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention.
For further information on Lunaphore and its products, please visit www.lunaphore.com.
Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data. For more information, please visit www.nucleai.ai.
